The global imaging agents market was valued at USD 9.91 billion in 2020 and is projected to grow at a CAGR of 3.9% during the forecast period. Factors driving the growth of the imaging agents market include increasing elderly populace suffering from end stage illness, the growing volume of CT and MRI inspections worldwide and increasing number of approvals of imaging agents.
Imaging agents are varied and can be used for diagnostic and therapeutic purposes, and have particular regulatory requirements and development concerns. Collective relationships amongst industry and academia can offer the best approach for the improvement of these agents. Further opportunities for growth and commercialization contain software specific for the examination of contrast-enhanced analyses. There are distinct respects for each class of imaging agents with regards to market growth and possible avenues for forthcoming development.
Regionally, North America accounted for the largest market share of the global imaging agents market attributable to developed healthcare infrastructure. Leading players of the global imaging agents market include General Electric Company, Piramal Imaging SA, Daiichi Sankyo Company Limited, Bracco Diagnostic Inc., Lantheus Medical Imaging Inc., Eisai Pharmaceuticals India Pvt. Ltd., Curium, Guerbet Company, Aytu BioScience Inc., Bayer Healthcare Pharmaceuticals among others.
Imaging Agents Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 19.35 billion|
|Growth Rate||CAGR of 3.9% during 2021-2028|
|Segment Covered||Application,End-user, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East & Africa|
|Key Players Profiled||General Electric Company, Piramal Imaging SA, Daiichi Sankyo Company Limited, Bracco Diagnostic Inc., Lantheus Medical Imaging Inc., Eisai Pharmaceuticals India Pvt. Ltd., Curium, Guerbet Company, Aytu BioScience Inc., Bayer Healthcare Pharmaceuticals among others.|
Key segments of the global imaging agents market
Application Overview, 2018-2028 (USD Billion)
- Gastrointestinal Disorders
- Neurology Disorders
End User Overview, 2018-2028 (USD Billion)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Diagnostic & imaging centers
Regional Overview, 2018-2028 (USD Billion)
- North America
- United Kingdom
- Asia Pacific
- South America
- Middle East & Africa
- South Africa
Reasons for the study
- Rapidly growing cancer and CVD population across the globe
- Rising volume of CT and MRI examinations globally
- The role of these tests in identifying the need for treatment/surgeries in interventional procedures and perioperative scans before surgeries
What does the report include?
- The study on the global imaging agents market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of application and end-use. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global imaging agents market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global imaging agents market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global imaging agents market
Latent developers in the imaging agents market comprise participants of the industry, academia, and joint partnerships amid the two entities. Diagnostic imaging agents are mostly less lethal than interventional drugs and several are extensively used, thus flooding the existing market and discouraging investigators from discovering new agents and tactics. In spite of the large quantities of imaging agents administered clinically, the fairly low reimbursement rates add to low profit margins, which normally daunts industry associates from discovering this group of drug development. Likewise, when employed for therapeutic or interventional signs, the huge initial investment is counterbalanced by the high monetary reward, which is alluring to these corporations. Academic interests comprise novel imaging methodologies and refining the diagnosis and treatment of patients, but the expenses accompanying Phase 1 and Phase 2 clinical trials build a hurdle for clinical translation in the academic setting. For that reason, collaborative partnerships amongst academia and pharmaceutical firms may bid the best prospect to diminish these obstacles in development and exploit potential benefits.
On the basis of application, the market is segmented into oncology, cardiology, gastrointestinal disorders and neurology disorders. Certain groups of radiotracers exemplify the promise and budding of molecular imaging, are in fairly advanced stages of clinical development, recognize unique biologic processes of prominence as biomarkers, and demonstrate the matters related to imaging agents development: imaging agents that detect proliferation, hypoxia, and amyloid. The biomarkers are of critical reputation in cancer (proliferation, hypoxia); infection, cardiovascular events (hypoxia); and neurodegenerative disease (amyloid). An understanding of the progress of these radiotracers will offer insight into imaging agent’s development.
North America dominated the market for imaging agents in 2020. Numerous available imaging agents for CT and MRI are long recognized and broadly used. Emerging agents have similarly lately been presented in the United States, mainly in the realm of US and NM/PET imaging. This collocation of diverse classes of imaging agents highlights the intricacy linked with the growth and development of imaging agents, which centers upon either the upgrading of standing agents or the development of innovative imaging drugs. The Food and Drug Administration (FDA) offers supervision in this course (Office of the Commissioner; Center for Drug Evaluation and Research, “Developing Medical Imaging Drug and Biological Products Part 1: Conduc”). To summarize their provided materials, if a contrast agent is now approved, it can be approved for use by a class of devices (e.g., CT, MRI, US), but if the explicit contrast agent needs definite software for elucidation, it may entail approval as a combination product, and the FDA Office of Combination Products can function as a cherished resource. Imaging software has conventionally been approved individually of contrast media and frequently as a constituent of imaging systems. Nevertheless, the sustained growth of imaging agents for NM/PET, which might involve dedicated software packages for examination and interpretation, may demand classification as combination products.